Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide

Arthritis & Rheumatism

Volumn 37, Issue 5, 1994, Pages 729-735

  Åkesson, Anita ^a   Scheja, Agneta ^a   Lundin, Anders ^a   Wollheim, Frank A ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; ANTACID AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CARBON MONOXIDE; CHLORAMBUCIL; COLLAGEN TYPE 3; CREATININE; CYCLOPHOSPHAMIDE; ENALAPRIL; HISTAMINE H2 RECEPTOR ANTAGONIST; OROSOMUCOID; PENICILLAMINE; PREDNISOLONE; TECHNETIUM SULFUR COLLOID TC 99M;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; ERYTHROCYTE SEDIMENTATION RATE; ESOPHAGUS FUNCTION; FEMALE; GLOMERULUS FILTRATION RATE; HEMATURIA; HUMAN; KIDNEY FUNCTION; LEUKOPENIA; LUNG ALVEOLITIS; LUNG COMPLIANCE; LUNG FIBROSIS; LUNG FUNCTION TEST; LUNG VOLUME; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SCLERODERMA; SYSTEMIC SCLEROSIS; THORAX RADIOGRAPHY; THROMBOCYTOPENIA; VITAL CAPACITY;

ADULT; AGED; CYCLOPHOSPHAMIDE; FEMALE; GLUCOCORTICOIDS; HEMATURIA; HUMANS; KIDNEY FUNCTION TESTS; LEUKOPENIA; LUNG; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROCOLLAGEN; PULMONARY FIBROSIS; SCLERODERMA, SYSTEMIC; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0028211614     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.1780370518     Document Type: Article

References (35)

1. Cellular infiltrates in scleroderma skin
2. 99mTc‐DTPA clearance
3. Lymphocytes in the skin of patients with progressive systemic sclerosis: quantification, subtyping, and clinical correlations
4. Soluble immunologic products in scleroderma sera
5. Localization of collagen mRNA in normal and scleroderma skin by in situ hybridization
6. Spontaneous production of fibronectin by alveolar macrophages in patients with scleroderma
7. Mortality in systemic sclerosis (scleroderma)
8. High resolution computed tomography in early scleroderma lung disease
9. Evaluation and management of scleroderma lung disease using bronchoalveolar lavage
10. Idiopathic pulmonary fibrosis: pretreatment bronchoalveolar lavage cellular consistents and their relationships with lung histopathology and clinical response to therapy
11. Visceral improvement following combined plasmapheresis and immunosuppressive drug therapy in progressive systemic sclerosis
12. Preliminary criteria for the classification of systemic sclerosis (scleroderma)
13. Organ manifestations in 100 patients with progressive systemic sclerosis
14. Esophageal dysfunction and radionuclide transit in progressive systemic sclerosis
15. Lung function in progressive systemic sclerosis is dominated by poorly compliant lungs and stiff airways
16. Standardized lung function testing: report from working party on “standardization of lung function tests,” European Community for Coal and Steel
17. Spirometric studies in normal subjects. I. Forced spirograms in subjects between 7–70 years of age
18. Spirometric studies in normal subjects. III. Static lung volumes and maximum voluntary ventilation in adults with a note to physical fitness
19. Effects of ageing alone on mechanical properties of the normal adult human lung
20. Pulmonary mechanics in normal men, studied with the flow regular method
21. A simple method for the determination of glomerular filtration rate
22. Rapid equilibrium radioimmunoassay for the amino‐terminal propeptide of human type III procollagen
23. Quantitative estimation of proteins by electro‐phoresis in agarose gel containing antibodies
24. Serial pulmonary function in systemic sclerosis
25. Longitudinal changes in lung function and respiratory symptoms in progressive systemic sclerosis
26. Pathologic observations in systemic sclerosis (scleroderma)
27. Clinical and demographic predictors of loss of pulmonary function in systemic sclerosis
28. Isolated diffusing capacity reduction in systemic sclerosis
29. Prolonged alkylating drug therapy is beneficial in systemic sclerosis (abstract)
30. Immunosuppression with chlorambucil, versus placebo, for scleroderma: results of a three‐year, parallel, randomized, double‐blind study
31. Treatment of systemic sclerosis
32. Cyclophosphamide and low‐dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease
33. Serum aminoterminal propeptide of type III procollagen in systemic sclerosis
34. Serum levels of aminoterminal type III procollagen peptide and hyaluronan predict mortality in systemic sclerosis
35. Raised concentrations of von Willebrand factor antigen in systemic sclerosis